Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd ...

Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

The PD-L1 Biomarker Testing Market offers opportunities driven by the rising incidence of non-small cell lung cancer and the ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Cancer immunotherapy has transformed oncology, yet many patients fail to respond or eventually develop resistance.

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...